Nimbus Discovery Obtains $24,000,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
    Nimbus Discovery
  • Mailing Address
    25 First Street Cambridge, MA 02141
  • Company Description
    Nimbus Discovery is applying advances in computer-based drug discovery to unlock fundamental biological pathways. Nimbus has already delivered selective, potent, and differentiated compounds within the first year for two disease targets, IRAK4 and ACC, which are pivotal to the progression of an aggressive subtype of non-Hodgkin’s lymphoma and obesity, respectively.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used to accelerate existing programs targeting IRAK4 and ACC, in inflammation, cancer and metabolic disease, and to expand the Nimbus pipeline to include a series of new targets addressing important medical conditions.
  • M&A Terms
  • Venture Investor
    Atlas Venture
  • Venture Investor
    SR One
  • Venture Investor
    Lilly Ventures
  • Venture Investor
    Cascade Investment

Trending on Xconomy